A PHASE 2/3, MULTICENTER, OPEN-LABEL PHASE
FOLLOWED BY A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO
EVALUATE THE EFFICACY AND SAFETY OF INFIGRATINIB IN CHILDREN WITH
HYPOCHONDROPLASIA: ACCEL 2/3
- Registry ID
- QBGJ398-304
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- QED THERAPEUTICS, INC.
- Start date
- 2025-06-20
- Last update
- 2025-03-26
Conditions
Related clinical trials
- PHASE 2, OPEN-LABEL, LONG-TERM, EXTENSION (OLE) STUDY OF INFIGRATINIB, AN FGFR 1-3-SELECTIVE TYROSINE KINASE INHIBITOR, IN CHILDREN WITH HYPOCHONDROPLASIA: ACCEL OLE
- A PHASE 3, OPEN-LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY
AND EFFICACY OF VOSORITIDE IN CHILDREN WITH HYPOCHONDROPLASIA
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VOSORITIDE IN CHILDREN WITH HYPOCHONDROPLASIA.
View on source registry